JP7097851B2 - 乱視のリスクを判定する方法 - Google Patents
乱視のリスクを判定する方法 Download PDFInfo
- Publication number
- JP7097851B2 JP7097851B2 JP2019081722A JP2019081722A JP7097851B2 JP 7097851 B2 JP7097851 B2 JP 7097851B2 JP 2019081722 A JP2019081722 A JP 2019081722A JP 2019081722 A JP2019081722 A JP 2019081722A JP 7097851 B2 JP7097851 B2 JP 7097851B2
- Authority
- JP
- Japan
- Prior art keywords
- snp
- genotype
- disease
- risk
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000009310 astigmatism Diseases 0.000 title description 4
- 238000000034 method Methods 0.000 claims description 34
- 230000002596 correlated effect Effects 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000012549 training Methods 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims 3
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 88
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 88
- 210000000349 chromosome Anatomy 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 239000000523 sample Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000007477 logistic regression Methods 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000013611 chromosomal DNA Substances 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013527 convolutional neural network Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010021093 hypospadias Diseases 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019081722A JP7097851B2 (ja) | 2019-04-23 | 2019-04-23 | 乱視のリスクを判定する方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019081722A JP7097851B2 (ja) | 2019-04-23 | 2019-04-23 | 乱視のリスクを判定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020178545A JP2020178545A (ja) | 2020-11-05 |
| JP2020178545A5 JP2020178545A5 (enrdf_load_stackoverflow) | 2022-03-15 |
| JP7097851B2 true JP7097851B2 (ja) | 2022-07-08 |
Family
ID=73022516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081722A Active JP7097851B2 (ja) | 2019-04-23 | 2019-04-23 | 乱視のリスクを判定する方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7097851B2 (enrdf_load_stackoverflow) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004173505A (ja) | 2002-11-22 | 2004-06-24 | Mitsuo Itakura | 疾患感受性遺伝子の同定方法並びにそれに用いるプログラムおよびシステム |
| JP2012094143A (ja) | 2010-10-27 | 2012-05-17 | Samsung Sds Co Ltd | バイオマーカー抽出装置および方法 |
| CN105256059A (zh) | 2015-11-20 | 2016-01-20 | 山东省眼科研究所 | Tuba3d基因在制备圆锥角膜诊断制品中的应用 |
| CN106282383A (zh) | 2016-10-08 | 2017-01-04 | 山东省眼科研究所 | Krt12基因在检测圆锥角膜中的应用 |
| CN106399564A (zh) | 2016-11-11 | 2017-02-15 | 山东省眼科研究所 | Ercc8基因在先天性白内障合并圆锥角膜检测中的应用 |
| WO2018200980A1 (en) | 2017-04-28 | 2018-11-01 | Avellino Lab Usa, Inc. | Methods for detecting alleles associated with keratoconus |
-
2019
- 2019-04-23 JP JP2019081722A patent/JP7097851B2/ja active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004173505A (ja) | 2002-11-22 | 2004-06-24 | Mitsuo Itakura | 疾患感受性遺伝子の同定方法並びにそれに用いるプログラムおよびシステム |
| JP2012094143A (ja) | 2010-10-27 | 2012-05-17 | Samsung Sds Co Ltd | バイオマーカー抽出装置および方法 |
| CN105256059A (zh) | 2015-11-20 | 2016-01-20 | 山东省眼科研究所 | Tuba3d基因在制备圆锥角膜诊断制品中的应用 |
| CN106282383A (zh) | 2016-10-08 | 2017-01-04 | 山东省眼科研究所 | Krt12基因在检测圆锥角膜中的应用 |
| CN106399564A (zh) | 2016-11-11 | 2017-02-15 | 山东省眼科研究所 | Ercc8基因在先天性白内障合并圆锥角膜检测中的应用 |
| WO2018200980A1 (en) | 2017-04-28 | 2018-11-01 | Avellino Lab Usa, Inc. | Methods for detecting alleles associated with keratoconus |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020178545A (ja) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020174538A (ja) | ２型糖尿病のリスクを判定する方法 | |
| JP7097853B2 (ja) | 妊娠高血圧症候群のリスクを判定する方法 | |
| JP7097851B2 (ja) | 乱視のリスクを判定する方法 | |
| JP2020178555A (ja) | 緑内障のリスクを判定する方法 | |
| JP7096784B2 (ja) | 妊娠糖尿病のリスクを判定する方法 | |
| JP7097846B2 (ja) | 胃炎のリスクを判定する方法 | |
| JP2020178589A (ja) | リウマチのリスクを判定する方法 | |
| JP2020178561A (ja) | 心筋梗塞及び／又は狭心症のリスクを判定する方法 | |
| JP7097845B2 (ja) | 近視のリスクを判定する方法 | |
| JP7097854B2 (ja) | 子宮筋腫のリスクを判定する方法 | |
| JP7099985B2 (ja) | 角膜疾患のリスクを判定する方法 | |
| JP7099984B2 (ja) | 白内障のリスクを判定する方法 | |
| JP7097849B2 (ja) | 過敏性腸症候群のリスクを判定する方法 | |
| JP7097855B2 (ja) | 歯周病のリスクを判定する方法 | |
| JP7099981B2 (ja) | 痛風のリスクを判定する方法 | |
| JP7101143B2 (ja) | 大腸がんのリスクを判定する方法 | |
| JP7099980B2 (ja) | 双極性障害のリスクを判定する方法 | |
| JP7097852B2 (ja) | 子宮内膜症のリスクを判定する方法 | |
| JP7097847B2 (ja) | 胃潰瘍のリスクを判定する方法 | |
| JP2020174625A (ja) | 過食症のリスクを判定する方法 | |
| JP2020178573A (ja) | 先天性股関節脱臼のリスクを判定する方法 | |
| JP2020178575A (ja) | 骨粗しょう症のリスクを判定する方法 | |
| JP2020178550A (ja) | 食物アレルギーのリスクを判定する方法 | |
| JP2020174638A (ja) | 慢性中耳炎のリスクを判定する方法 | |
| JP2020178536A (ja) | アレルギー性結膜炎のリスクを判定する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200609 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220304 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220530 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220628 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7097851 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |